Beamr video compression achieves up to 50% improvement for AVs
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Chief Scientific Officer Gary K. Lee reported selling a total of 267 shares of common stock on August 11 and 12, 2025. The sales, which totaled $2,784, were executed in two separate transactions with prices ranging from $10.338 to $10.526 per share. According to InvestingPro data, the company, currently valued at $163 million, has shown strong returns over the past three months despite its weak overall financial health score.
On August 11, Lee sold 131 shares of Lyell Immunopharma at a weighted average price of $10.526, with prices ranging from $10.045 to $11.00 per share. Following this transaction, Lee directly owns 9,093 shares.
The following day, August 12, Lee sold 136 shares at a weighted average price of $10.338, with prices ranging from $10.120 to $10.415 per share. Following this transaction, Lee directly owns 8,957 shares.
The sales were automatically executed to cover tax withholding obligations from the settlement of vested restricted stock units.
In other recent news, Lyell Immunopharma has made significant strides with its LYL314 therapy, which has shown promising results in a clinical trial. The therapy achieved an 88% overall response rate and a 72% complete response rate in patients with large B-cell lymphoma. Notably, 71% of those achieving a complete response maintained it for at least six months. Additionally, Lyell Immunopharma has entered into a securities purchase agreement to raise up to $100 million through a private placement. The initial closing is expected to bring in approximately $50 million, with shares priced at $13.32 each. These developments reflect Lyell Immunopharma’s ongoing efforts to advance its clinical-stage therapies and secure funding for future endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.